Bitcoin (BTC) has continued to plough a furrow to the downside, dropping below $108,000. However, the number one cryptocurrency is now heavily oversold and therefore a reversal makes perfect sense. When could this potential reversal arrive, and what are the upside targets?Bitcoin (BTC) has continued to plough a furrow to the downside, dropping below $108,000. However, the number one cryptocurrency is now heavily oversold and therefore a reversal makes perfect sense. When could this potential reversal arrive, and what are the upside targets?

Bitcoin (BTC) Nearing a Bottom? Prepare for a Potential Reversal

Bitcoin (BTC) has continued to plough a furrow to the downside, dropping below $108,000. However, the number one cryptocurrency is now heavily oversold and therefore a reversal makes perfect sense. When could this potential reversal arrive, and what are the upside targets?

Has $BTC formed a double bottom?

Source: TradingView

The odd pattern that had been forming since mid-July has become two descending channels. First, the gently sloping one that found a bottom in early August, and now this steeper descending channel that just might have found a bottom where the price is now. In fact, the $BTC price action might have made a small double bottom reversal pattern, similar to the slightly bigger one that marked the bottom of the previous descending channel. The green arrow traces a possible path for this next potential recovery.

The 4-hour Stochastic RSI indicators are coming down and should have bottomed out by the end of the day, or could even start reversing now. Therefore, this prospective reversal could start to take place from here on in. All the other short-term Stochastic RSI momentum indicators are at the bottom, and even on the higher time frames, the daily, and even the weekly are at the bottom or about to arrive there. As far as price momentum goes the bulls could be back in control very soon.

50-day simple moving average rolls over

Source: TradingView

The daily time frame reveals how the $BTC price action has lost the important support at $109,000. Also, it can be seen that the 50-day SMA (blue line) has turned down. A reversal back to the upside will be needed to stop it dipping under the 100-day SMA (green line). Below this, the 200-day SMA (red line) generally marks the bottom boundary of the bull market, although this has been infringed each time there has been a big correction. 

Weekly Stochastic RSI indicators about to reset

Source: TradingView

The weekly chart is starting to look much more positive. In the time that it has taken to write this article till now, the $BTC price has moved up strongly, putting on more than 1% for Monday already. It could be that the major $109,000 level will be considered to have held, as long as this weekly candle is a good one or at least closes above this level.

The major plus for the bulls on this chart is the Stochastic RSI. The indicators are now approaching the bottom and possibly as soon as next week they will have bottomed and could have started to angle back up. If this happens, it could signal the upside price momentum that will be needed to take the price back to the high. Firstly, the bulls need to flip the $112,000 horizontal level back into support. After this, $119,500 marks the candle body closes so this will be a major level to get above. Could this be the start of the next surge to new highs, or are Bitcoin holders about to be disappointed yet again?

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$95,484.97
$95,484.97$95,484.97
-1.33%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26